Bionano Genomics, Inc. (BNGO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '17: 9.5M Q1 '18: 9.6M Q2 '18: 10.7M Q3 '18: 10.8M Q4 '18: 12M Q1 '19: 12.1M Q2 '19: 10.9M Q3 '19: 11.4M Q4 '19: 10.1M Q1 '20: 9.4M Q2 '20: 8.4M Q3 '20: 7.3M Q4 '20: 8.5M Q1 '21: 10.5M Q2 '21: 13.2M Q3 '21: 15.7M Q4 '21: 18M Q1 '22: 20.5M Q2 '22: 23.3M Q3 '22: 25.9M Q4 '22: 27.8M Q1 '23: 29.5M Q2 '23: 31.5M Q3 '23: 33.6M Q4 '23: 36.1M Q1 '24: 37.5M Q2 '24: 36.6M Q3 '24: 33.3M Q4 '24: 30.8M Q1 '25: 28.5M Q2 '25: 27.4M Q3 '25: 28.7M Q4 '25: 28.5M Q1 '26: 28.7M Q2 '26: 30.2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

-5M 0 5M 10M 15M Q4 '17: 3.5M Q1 '18: 3.9M Q2 '18: 4.9M Q3 '18: 3.6M Q4 '18: 3.3M Q1 '19: 3.1M Q2 '19: 2.1M Q3 '19: 3.3M Q4 '19: 3.4M Q1 '20: 2.9M Q2 '20: 2.9M Q3 '20: 2.7M Q4 '20: 2.8M Q1 '21: 3.5M Q2 '21: 4.4M Q3 '21: 4.8M Q4 '21: 3.9M Q1 '22: 3.7M Q2 '22: 3.7M Q3 '22: 4.4M Q4 '22: 5.9M Q1 '23: 7.2M Q2 '23: 8M Q3 '23: 8.9M Q4 '23: 9.6M Q1 '24: 10.3M Q2 '24: 10.6M Q3 '24: -599K Q4 '24: 380K Q1 '25: 494K Q2 '25: 1.4M Q3 '25: 13.2M Q4 '25: 13.2M Q1 '26: 13.5M Q2 '26: 14.3M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q2 '18: -18.6M Q3 '18: -19.6M Q4 '18: -20.4M Q1 '19: -22.3M Q2 '19: -25.1M Q3 '19: -24.8M Q4 '19: -25.9M Q1 '20: -29.5M Q2 '20: -30M Q3 '20: -34.6M Q4 '20: -38.5M Q1 '21: -40M Q2 '21: -49M Q3 '21: -59.4M Q4 '21: -77.1M Q1 '22: -95.9M Q2 '22: -111.5M Q3 '22: -123M Q4 '22: -131.7M Q1 '23: -139.6M Q2 '23: -146.8M Q3 '23: -227.8M Q4 '23: -215.2M Q1 '24: -208.5M Q2 '24: -186.3M Q3 '24: -117M Q4 '24: -104M Q1 '25: -81.3M Q2 '25: -72.1M Q3 '25: -36.7M Q4 '25: -33.3M Q1 '26: -32.8M Q2 '26: -32.2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '17: 13.2M Q1 '18: 3.7M Q2 '18: -6.3M Q3 '18: -6.2M Q4 '18: -18.5M Q1 '19: -22.5M Q2 '19: -26.9M Q3 '19: -28.3M Q4 '19: -29.8M Q1 '20: -32.5M Q2 '20: -32.9M Q3 '20: -37.3M Q4 '20: -41.1M Q1 '21: -40.5M Q2 '21: -51.3M Q3 '21: -61.2M Q4 '21: -72.4M Q1 '22: -92.4M Q2 '22: -105.8M Q3 '22: -116.9M Q4 '22: -132.6M Q1 '23: -139.8M Q2 '23: -146.5M Q3 '23: -227.3M Q4 '23: -232.5M Q1 '24: -226.8M Q2 '24: -204.1M Q3 '24: -135.8M Q4 '24: -112M Q1 '25: -83.7M Q2 '25: -74.3M Q3 '25: -38.6M Q4 '25: -26.4M Q1 '26: -31.6M Q2 '26: -32.2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q4 '17: 6M Q1 '18: 5.7M Q2 '18: 5.8M Q3 '18: 7.2M Q4 '18: 8.7M Q1 '19: 9M Q2 '19: 8.8M Q3 '19: 8.1M Q4 '19: 6.8M Q1 '20: 6.5M Q2 '20: 5.5M Q3 '20: 4.6M Q4 '20: 5.7M Q1 '21: 7M Q2 '21: 8.8M Q3 '21: 10.9M Q4 '21: 14.1M Q1 '22: 16.8M Q2 '22: 19.6M Q3 '22: 21.5M Q4 '22: 21.9M Q1 '23: 22.4M Q2 '23: 23.5M Q3 '23: 24.7M Q4 '23: 26.6M Q1 '24: 27.2M Q2 '24: 26M Q3 '24: 33.9M Q4 '24: 30.4M Q1 '25: 28M Q2 '25: 26M Q3 '25: 15.5M Q4 '25: 15.3M Q1 '26: 15.2M Q2 '26: 15.8M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '18: -18.7M Q4 '18: -19.9M Q1 '19: -19.7M Q2 '19: -23.1M Q3 '19: -24.2M Q4 '19: -29.5M Q1 '20: -31M Q2 '20: -31.9M Q3 '20: -35.6M Q4 '20: -38.3M Q1 '21: -44.2M Q2 '21: -49.4M Q3 '21: -58.4M Q4 '21: -71.9M Q1 '22: -90.5M Q2 '22: -106.4M Q3 '22: -115.9M Q4 '22: -124.8M Q1 '23: -124.7M Q2 '23: -133.1M Q3 '23: -129.9M Q4 '23: -125.2M Q1 '24: -120.9M Q2 '24: -105.2M Q3 '24: -92.2M Q4 '24: -68.9M Q1 '25: -43.6M Q2 '25: -26.1M Q3 '25: -18.7M Q4 '25: -16.3M Q1 '26: -19.3M Q2 '26: -20.5M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '18: -19.3M Q4 '18: -20.3M Q1 '19: -20M Q2 '19: -23.2M Q3 '19: -24.3M Q4 '19: -29.6M Q1 '20: -31.1M Q2 '20: -31.9M Q3 '20: -35.6M Q4 '20: -38.3M Q1 '21: -44.2M Q2 '21: -49.5M Q3 '21: -58.8M Q4 '23: -126.9M Q1 '24: -122.3M Q2 '24: -106.1M Q3 '24: -93M Q4 '24: -69M Q1 '25: -43.6M Q2 '25: -26.1M Q3 '25: -18.7M Q4 '25: -16.3M Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q2 '20: 90.9M Q3 '20: 132.9M Q1 '21: 263.9M Q2 '21: 278.9M Q3 '21: 280.2M Q1 '22: 284.6M Q2 '22: 28.6M Q3 '22: 29M Q1 '23: 30.2M Q2 '23: 31.5M Q3 '23: 35M Q1 '24: 879K Q2 '24: 1.1M Q3 '24: 1.4M Q1 '25: 2.7M Q2 '25: 3.4M Q3 '25: 5.3M Q1 '26: 11M Q2 '26: 11.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-600.00 -400.00 -200.00 0.00 200.00 400.00 600.00 Q2 '18: -5.85 Q3 '18: -4.74 Q4 '18: -3.39 Q1 '19: -3.00 Q2 '19: -2.73 Q3 '19: -2.69 Q4 '19: -2.00 Q1 '20: -1.53 Q2 '20: -0.91 Q3 '20: -0.40 Q4 '20: -0.52 Q1 '21: -0.26 Q2 '21: -0.24 Q3 '21: -0.23 Q4 '21: -0.26 Q1 '22: -0.33 Q2 '22: -1.39 Q3 '22: -2.42 Q4 '22: -3.64 Q1 '23: -4.76 Q2 '23: -4.87 Q3 '23: -6.99 Q4 '23: -408.44 Q1 '24: -442.96 Q2 '24: -456.13 Q3 '24: -483.83 Q4 '24: -89.03 Q1 '25: -54.43 Q2 '25: -42.01 Q3 '25: -12.68 Q4 '25: -4.76 Q1 '26: -4.37 Q2 '26: -3.02 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.